REAL TIME ANGIOTENSIN MONITOR FOR SALT SENSITIVITY

盐敏感性实时血管紧张素监测仪

基本信息

  • 批准号:
    7951173
  • 负责人:
  • 金额:
    $ 0.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There will be no control subjects. 35 healthy subjects, age 18-65 will undergo electrophysiologic measures using ECG, impedance cardiography, EEG, transcranial Doppler sonography, Temperature and movement measurements, heart rate and blood pressure monitoring before and after ingesting an oral salt load a total of 2500 mg of Sodium in tablet form. The low frequency band changes in response to oral salt load will analyzed and correlated with blood pressure changes in response to the oral salt load. Serum angiotensin II, norepinephrine,sodium and potassium levels will also be evaluated before and after oral salt loading. All subjects will follow the same protocol. All research procedures will be explained orally and in written form. All subjects will sign informed consent forms prior to beginning any research procedures. Screening and Evaluation, Day 1 and Day 2 of the study will be performed by Cardiology research staff. Participant will come to GCRC for the Day 3 of study for 4 hours outpatient visit only. On Day 1 subjects will come to Cardiology Clinical Research facility, UMMS for orientation and informed consent. A medical history and baseline blood pressure measurements will be obtained. Subjects will be given instructions for the low salt diet based on guidance from a registered dietician. Subjects will be provided with a log book to record consumed food and fluids, collected urine, and exercise activity. Urine collection containers will also be provided. On Day 2, subjects will follow the salt restricted diet as outlined by the registered dietician. They will maintain food and fluid logs and collect urine samples in provided containers for 12 hours prior to the beginning of the study (i.e. from 9 PM on the night prior) as per the procedure listed prior. Subjects will not come for a laboratory visit on Day 2. Day 3, GCRC visit: subjects will continue to follow the salt restricted diet as outlined by the registered dietician until they come to GCRC at 8-9 AM. Physiologic measurements as listed above will be recorded. An indwelling peripheral intravenous catheter will be placed for blood draw. Approximately 42 minutes of baseline blood pressure and heart rate/low frequency band measurements will be obtained. During the baseline period , subjects will be asked to breathe at a constant rate (0.25 Hz or a complete breath every 4 seconds) for 6 minutes to standardize respiratory variations in heart rate variability; then subjects will perform a simple cognitive task (such as pushing a button when a circle appears on a television screen) for 6 minutes, and then subjects will sit still without any prompts for 6 minutes; one minute will be allowed between each condition for instructions and transition. This cycle will be repeated twice to obtain approximately 42 minutes of baseline data. Blood samples (15 mls or approximately 3 teaspoons at each sampling time) will be drawn at minutes 28 (end of the second paced breathing) and 35 (end of the second cognitive task) for measurements of angiotensin II, norepinephrine, sodium, and potassium. The subjects will then be asked to consume a total of 2500 mg of sodium in tablet form. Approximately 126 minutes of physiological monitoring will then be obtained. Six cycles of paced breathing (6 min), cognitive tasks (6 min), and relaxation without any prompts (6 min) will be repeated to gather the approximately minutes of physiological data post oral salt loading. 15ml of blood (approximately 3 teaspoons) will be collected at minutes 98 (end of the fifth paced breathing after the salt load) and 105 (end of the fifth cognitive task after the salt load) for measurement of serum angiotensin II, norepinephrine, sodium, and potassium levels post oral salt load. Total amount of the blood drawn on day 3 will be approximately 60 mls or 12 teaspoons.
该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员(PI)可能已经从其他NIH来源获得了主要资金, 因此可以在其他清晰的条目中代表。列出的机构是 对于中心,这不一定是调查员的机构。 将没有控制主题。 35名健康受试者,18-65岁的健康受试者将使用ECG,阻抗心脏摄影,脑电图,经颅多普勒超声检查,温度和运动测量,心率和血压监测前后,在摄入口服盐负荷之前和之后,总计2500毫克钠的含量。对口腔盐负荷响应的低频带的变化将分析并与口服盐负荷响应的血压变化相关。血清血管紧张素II,去甲肾上腺素,钠和钾水平也将在口服盐负荷前后进行评估。所有主题将遵循相同的协议。所有研究程序将以口头和书面形式进行解释。所有受试者将在开始任何研究程序之前签署知情同意书。筛查和评估,研究人员将进行研究的第1天和第2天。参与者将仅在研究的第三天来到GCRC 4小时门诊就诊。在第1天,受试者将进入心脏病学临床研究机构,取向和知情同意。将获得病史和基线血压测量。根据注册营养师的指导,将为受试者提供低盐饮食的说明。将为受试者提供一本日志,以记录消耗的食物和液体,收集的尿液和运动活动。还将提供尿液收集容器。在第2天,受试者将遵循注册营养师概述的盐限制饮食。他们将根据先前列出的步骤来维护食物和液体原木,并在研究开始前的12小时内(即从前晚上9点开始)收集尿液样品。受试者将不会在第2天进行实验室访问,GCRC访问:受试者将继续遵循注册营养师概述的盐限制饮食,直到他们于8-9 AM来到GCRC。将记录上述生理测量值。将放置留置周围静脉内导管以进行抽血。将获得大约42分钟的基线血压和心率/低频带测量。在基线期间,将要求受试者以恒定的速度(0.25 Hz或每4秒完全呼吸)呼吸6分钟,以标准化心率变异性的呼吸变化;然后,受试者将执行一个简单的认知任务(例如,电视屏幕上出现圆圈时按下按钮)持续6分钟,然后受试者将静止不动,没有任何提示,请持续6分钟;每种条件之间将允许一分钟进行说明和过渡。该周期将重复两次,以获得大约42分钟的基线数据。用于测量血管紧张素II,去甲肾上腺素,钠和钾剂,将在分钟28(第二个节奏呼吸的结尾)和35(第二个认知任务的结束)和35(第二个认知任务结束)时抽取血液样本(在每个采样时间为15茶匙)和35分钟(第二个节奏呼吸的结束)和35(第二个认知任务结束)。然后,将要求受试者以片剂形式消耗2500毫克的钠。然后将获得大约126分钟的生理监测。六个节奏的节奏呼吸(6分钟),认知任务(6分钟)和放松没有任何提示(6分钟),以收集口服盐加载后大约分钟的生理数据。将在第98分钟(盐负荷后第五个节奏的呼吸结束)和105(盐负荷后的第五个认知任务结束)时收集15毫升的血液(约3茶匙),以测量血清血管紧张素II,去甲肾上腺素,钠和钾盐水平。在第3天抽血的总数约为60毫升或12茶匙。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MANDEEP R MEHRA其他文献

MANDEEP R MEHRA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MANDEEP R MEHRA', 18)}}的其他基金

Docosahexaenoic Acid for Treatment of Heart Failure
二十二碳六烯酸治疗心力衰竭
  • 批准号:
    7867093
  • 财政年份:
    2010
  • 资助金额:
    $ 0.7万
  • 项目类别:
Docosahexaenoic Acid for Treatment of Heart Failure
二十二碳六烯酸治疗心力衰竭
  • 批准号:
    8053762
  • 财政年份:
    2010
  • 资助金额:
    $ 0.7万
  • 项目类别:

相似国自然基金

血管紧张素II活化的钙振荡在TBI后PSH相关的神经功能损害中的作用与机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
PKCε-Rab11介导KCNQ1通道膜蛋白下调促进血管紧张素II诱导的心肌肥厚致心律失常的机制研究
  • 批准号:
    82204397
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
血管紧张素II活化的钙振荡在TBI后PSH相关的神经功能损害中的作用与机制研究
  • 批准号:
    82201519
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
血管紧张素II2型受体在血管损伤中抑制周围脂肪组织功能失调的作用及机制研究
  • 批准号:
    82200458
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
血管紧张素II2型受体在血管损伤中抑制周围脂肪组织功能失调的作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

ANG1-7 as an intervention for Alzheimer's Disease.
ANG1-7 作为阿尔茨海默病的干预措施。
  • 批准号:
    10592577
  • 财政年份:
    2023
  • 资助金额:
    $ 0.7万
  • 项目类别:
RECK in Adverse Cardiac Remodeling and Heart Failure
RECK 在不良心脏重构和心力衰竭中的应用
  • 批准号:
    10368301
  • 财政年份:
    2022
  • 资助金额:
    $ 0.7万
  • 项目类别:
RECK in Adverse Cardiac Remodeling and Heart Failure
RECK 在不良心脏重构和心力衰竭中的应用
  • 批准号:
    10655310
  • 财政年份:
    2022
  • 资助金额:
    $ 0.7万
  • 项目类别:
Targeting ADAM17 maturation in resistant hypertension.
靶向顽固性高血压中 ADAM17 的成熟。
  • 批准号:
    10608153
  • 财政年份:
    2022
  • 资助金额:
    $ 0.7万
  • 项目类别:
Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergics
转化药物流行病学:抗高血压药和强抗胆碱能药的神经保护和神经毒性
  • 批准号:
    10672375
  • 财政年份:
    2021
  • 资助金额:
    $ 0.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了